Esomeprazole Sodium - CAS 161796-78-7
Catalog number:
161796-78-7
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C17H18N3O3S.Na
Molecular Weight:
367.4
COA:
Inquire
Targets:
Proton Pump
Description:
Esomeprazole sodium (Nexium) suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
MSDS:
Inquire
1.[In vitro susceptibility of Trichomonas vaginalis to metronidazole, ornidazole and proton pump inhibitors pantoprazole and esomeprazole].
Aksoy Gökmen A1, Girginkardeşler N, Kilimcioğlu AA, Şirin MC, Özbilgin A. Mikrobiyol Bul. 2016 Jan;50(1):133-9.
The current treatment of trichomoniasis is based on the use of 5-nitroimidazole derivatives. Although metronidazole is reliable, inexpensive and highly effective against anaerobic microorganisms and protozoa, the development of metronidazole-resistant T.vaginalis strains pose to an increasing problem. Nitroimidazoles are compounds having azomycin (2-nitroimidazole) chemical structure and are obtained from Streptomyces strains. Benzimidazole, which is found in the structure of proton pump inhibitors, is also present in the other components that have antiprotozoal activity. In this study, the in vitro susceptibility of T.vaginalis against metronidazole, ornidazole, and the proton pump inhibitors which are tested recently as antiprotozoal agents; pantoprazole and esomeprazole was investigated. For this purpose a clinical T.vaginalis strain which was formerly isolated and stored after cryopreservation process in our laboratory was used. Minimum inhibitory concentration (MIC) and minimum lethal concentration (MLC) values of those agents against to this strain were determined in vitro by dilution method in 24-well cell culture plates.
2.Crystallization of Esomeprazole Magnesium Water/Butanol Solvate.
Skieneh J1, Khalili Najafabadi B2, Horne S3,4, Rohani S5. Molecules. 2016 Apr 23;21(4). pii: E544. doi: 10.3390/molecules21040544.
The molecular structure of esomeprazole magnesium derivative in the solid-state is reported for the first time, along with a simplified crystallization pathway. The structure was determined using the single crystal X-ray diffraction technique to reveal the bonding relationships between esomeprazole heteroatoms and magnesium. The esomeprazole crystallization process was carried out in 1-butanol and water was utilized as anti-solvent. The product proved to be esomeprazole magnesium tetrahydrate with two 1-butanol molecules that crystallized in P6₃ space group, in a hexagonal unit cell. Complete characterization of a sample after drying was conducted by the use of powder X-ray diffraction (PXRD), ¹H-nuclear magnetic resonance (NMR), thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), infrared spectroscopy (IR), and dynamic vapor sorption (DVS). Investigation by ¹H-NMR and TGA has shown that the solvent content in the dried sample consists of two water molecules and 0.
3.[10-day triple therapy with esomeprazole 40 mg/12 h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection].
Campillo A1, Amorena E2, Ostiz M2, Kutz M2, LaIglesia M2. Gastroenterol Hepatol. 2016 Apr 12. pii: S0210-5705(16)30013-9. doi: 10.1016/j.gastrohep.2016.03.002. [Epub ahead of print]
INTRODUCTION: Quadruple concomitant non-bismuth therapy has recently become the most widely prescribed first-line treatment for Helicobacter pylori infection in Spain. Whether optimized conventional triple therapy can achieve comparable efficacy rates remains to be seen.
4.Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease.
Bayerdörffer E1, Bigard MA2, Weiss W3, Mearin F4, Rodrigo L5, Dominguez Muñoz JE6, Grundling H7, Persson T8, Svedberg LE8, Keeling N8, Eklund S8. BMC Gastroenterol. 2016 Apr 14;16(1):48. doi: 10.1186/s12876-016-0448-x.
BACKGROUND: Most patients with gastroesophageal reflux disease experience symptomatic relapse after stopping acid-suppressive medication. The aim of this study was to compare willingness to continue treatment with esomeprazole on-demand versus continuous maintenance therapy for symptom control in patients with non-erosive reflux disease (NERD) after 6 months.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Proton Pump Products


CAS 117976-90-6 Rabeprazole Sodium

Rabeprazole Sodium
(CAS: 117976-90-6)

The sodium salt form of Rabeprazole which is a partially reversible inhibitor of gastric proton pump and could be used in the treatment of sorts of gastrointest...

CAS 102625-70-7 Pantoprazole

Pantoprazole
(CAS: 102625-70-7)

Pantoprazole, an irreversible protonpump inhibitor, inhibits the final step of the production ofgastric acid by binding to the sites of H+/K+ ATPase system in g...

CAS 103577-45-3 Lansoprazole.

Lansoprazole.
(CAS: 103577-45-3)

Lansoprazole is a proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid.

CAS 73590-58-6 Omeprazole

Omeprazole
(CAS: 73590-58-6)

Omeprazole is a proton pump inhibitor used in the treatment of dyspepsia. It binds to the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase)...

CAS 135779-82-7 Bamaquimast

Bamaquimast
(CAS: 135779-82-7)

Bamaquimast is an orally active inhibitor of proton pump with anti-inflammatory and antiasthmatic effects.

CAS 335299-59-7 Tenatoprazole sodium

Tenatoprazole sodium
(CAS: 335299-59-7)

Tenatoprazole is a novel proton pump inhibitor which is similar to the chemical structure of omeprazole, a widely used proton pump inhibitor. Tenatoprazole belo...

CAS 164579-32-2 Pantoprazole sodium hydrate

Pantoprazole sodium hydrate
(CAS: 164579-32-2)

Pantoprazole sodium hydrate is a proton pump inhibitor which acts as selective inhibiton of H+/K+-ATPase. With antiulcerative effects in vivo, it treats or amel...

CAS 138530-94-6 Dexlansoprazole

Dexlansoprazole
(CAS: 138530-94-6)

Dexlansoprazole is a proton pump inhibitor that is marketed by Takeda Pharmaceuticals for the treatment of erosive esophagitis and gastro-oesophageal reflux dis...

Esomeprazole magnesium salt
(CAS: 1198768-91-0)

The magnesium salt form of Esomeprazole which is a proton pump inhibitor so that could be probably useful in the treatment of sorts of digestive tract diseases ...

CAS 138786-67-1 Pantoprazole sodium

Pantoprazole sodium
(CAS: 138786-67-1)

The sodium salt form of Pantoprazole, a gastic proton pump inhibitor, could be used in the treatment of ulceration and some diseases induced by gastroesophageal...

CAS 161796-78-7 Esomeprazole Sodium

Esomeprazole Sodium
(CAS: 161796-78-7)

Esomeprazole sodium (Nexium) suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell.

Lansoprazole sodium
(CAS: 226904-00-3)

Lansoprazole sodium is the sodium salt form of Lansoprazole. Lansoprazole, a substituted benzimidizole, is proton pump inhibitor, is a proton pump inhibitor whi...

CAS 161796-84-5 Esomeprazole potassium

Esomeprazole potassium
(CAS: 161796-84-5)

Esomeprazole potassium is a proton pump inhibitor which acts as selective inhibiton of H+/K+-ATPase. With antiulcerative effects in vivo, it treats or ameliorat...

CAS 117976-89-3 Rabeprazole

Rabeprazole
(CAS: 117976-89-3)

Rabeprazole, a partially reversible inhibitor of gastric proton pump, could be used in the treatment of sorts of gastrointestinal disease especially peptic ulce...

CAS 261944-46-1 Soraprazan

Soraprazan
(CAS: 261944-46-1)

Soraprazan, also known as BY359, is a reversible, and fast-acting inhibitor of gastric H+/K+ ATPase, used as anti-secretory drug.

Chemical Structure

CAS 161796-78-7 Esomeprazole Sodium

Quick Inquiry

Verification code

Featured Items